C4 Therapeutics, Inc.
CCCC
$2.61
-$0.08-2.97%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -1.91% | 73.76% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -1.91% | 73.76% | |||
| Cost of Revenue | -370.43% | -0.79% | |||
| Gross Profit | 650.83% | 25.21% | |||
| SG&A Expenses | 2.90% | 1.75% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -2.14% | -0.16% | |||
| Operating Income | 2.26% | 16.92% | |||
| Income Before Tax | 36.69% | -23.62% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 36.31% | -23.62% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 36.31% | -23.62% | |||
| EBIT | 2.26% | 16.92% | |||
| EBITDA | 2.16% | 16.74% | |||
| EPS Basic | 60.43% | -20.99% | |||
| Normalized Basic EPS | 38.46% | 23.40% | |||
| EPS Diluted | 60.43% | -20.99% | |||
| Normalized Diluted EPS | 38.46% | 23.40% | |||
| Average Basic Shares Outstanding | 60.94% | 2.19% | |||
| Average Diluted Shares Outstanding | 60.94% | 2.19% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||